Glioblastoma Multiforme is a fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. Glioblastoma multiforme usually occurs in adults and affects the brain more often than the spinal cord. Also called GBM, glioblastoma, and grade IV astrocytoma.
Lab-grown brain organoids developed from a patient's own glioblastoma, the most aggressive and common form of brain cancer, may hold the answers on how to best treat it.
A new engineering solution may help deliver tumor killing drugs directly to the brain tumor without the toxic body effects of systemic chemotherapy. The new study published in the journal Nature Scientific Reports reports on the use of coaxial electrospinning, an industrial fabrication technology, in the production of membranes that incorporate drugs to treat glioblastoma multiforme (GBM), an aggressive cancer of the brain.
Researchers from the University of São Paulo in Brazil have developed a strategy for treating the most aggressive type of brain cancer in adults that combines a photoactive molecule and a chemotherapeutic agent - both encapsulated in protein-lipid nanoparticles.
Chemists from Far Eastern Federal University's School of Natural Sciences developed a new method to synthesize biologically active derivatives of fascaplysin -- cytotoxic pigment of a sea sponge. For the first time, they got a sufficient amount of 3-bromofascaplysin and 3,10-dibromofascaplysin, which were known before but were not available for study.
Mount Sinai researchers have identified a targeted therapy for adolescent patients with neuroblastoma, a deadly pediatric nerve cancer, who would otherwise have no treatment options, according to a study published in October in Cancer Cell.
Children with recurrent brain tumors or newly diagnosed, particularly aggressive tumors called diffuse intrinsic pontine gliomas are being enrolled in the first study to examine the efficacy of a drug that inhibits an enzyme these tumors use to protect themselves from the child's natural immune response.
The research team of Miguel Hernández Univeristy (UMH) professor Salvador Martínez and the team of researcher Rut Valdor, from the University of Murcia, have showed how the glioblastoma - the most common brain cancer - "hijacks" the defensive cells that surround the blood vessels of the brain to deactivate their anti-tumour action, and forces them to work to spread the tumour.
Investigators at the University of Cincinnati are studying whether or not a modified Atkins-type ketogenic diet could help make treatments for a common, but dangerous, type of brain cancer called glioblastoma more effective.
Glioblastoma is the most frequent and aggressive brain cancer due to its ability to escape the immune system. However, the way in which this tumor manages to induce this immune tolerance was not known in detail.
Scientists at the University of Sussex could be a step closer to developing the first-ever blood test to diagnose the most aggressive type of brain cancer, glioblastoma.
Glioblastoma, a cancer that arises in the brain's supporting glial cells, is one of the worst diagnoses a child can receive. The grade IV, highly malignant tumor aggressively infiltrates healthy brain tissue, and most children die of the disease within one to two years of diagnosis, similar to adults.
A combination of chemotherapy drugs during brain cancer surgery using a biodegradable paste, leads to long-term survival, researchers at the University of Nottingham have discovered.
Using human cancer cells, tumor and blood samples from cancer patients, researchers at Johns Hopkins Medicine have uncovered the role of a neurotransmitter in the spread of aggressive cancers. Neurotransmitters are chemical "messengers" that transmit impulses from neurons to other target cells.
Scientists from Far Eastern Federal University in cooperation with colleagues from Blokhin Russian Cancer Research Center, Switzerland, and Sweden for the first time studied proteins, which constitute WNT signaling pathway of the cancer stem cells of glioblastoma multiforme (GBM CD133+ CSCs), one of the most aggressive brain tumors.
University at Buffalo researchers have developed a new method to more accurately predict tumor growth rates, a crucial statistic used to schedule screenings and set dosing regimens in cancer treatment.
How does cancer spread? While studying human brain tumor cells, a team of scientists at the Research Institute of the McGill University Health Centre found some answers to this crucial, yet so far unanswered question.
Today, Penn Medicine is announcing the newest Translational Center of Excellence in the Abramson Cancer Center, focused on Glioblastoma Multiforme, the most common and lethal form of brain cancer.
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the presentation today of updated preliminary results from its ongoing Phase 1 clinical study of DCC-2618, the company's broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors as a proffered paper presentation at the European Society of Medical Oncology 2018 Congress in Munich, Germany.
Zika virus infection is a dreaded one that can lead to severe brain damage in the unborn babies of mothers who get it.
A Ludwig Cancer Research study explains why a particular mutation in the epidermal growth factor receptor, a cell surface protein, results in more aggressive tumors and poorer overall survival of patients diagnosed with the brain cancer glioblastoma multiforme.